Oligonucleotide Synthesis Patents: Top Companies & Trends 2026
- Filing has cooled since its 2017 peak. 67 filings that year versus a 2022 midpoint of 38, pointing to a field whose claim space was staked out early rather than one still accelerating.
- The top of the ranking is concentrated but not locked up. The five largest assignees hold 23.0% of all 1,001 records in scope, and the leading ten hold 35.7% — real concentration, with a long tail behind it.
- Nucleic-acid chemistry dominates the classification mix. C07H covers 88.3% of records, while adjacent process classes like B01J (10.1%) and G01N (9.0%) are comparatively thin.
What this landscape covers
This dataset tracks 1,001 published records filed between 2015 and mid-2026 that combine oligonucleotide synthesis, phosphoramidite chemistry or oligonucleotide manufacturing language with claim or description terms tied to coupling yield, solvent consumption, purification, solid supports or metric-ton scale-up. The scope sits at the intersection of nucleic-acid chemistry (C07H21), genetic engineering (C12N15) and adsorption/catalysis process art (B01J20) — the three classification families a synthesis or scale-up patent is likely to touch.
Because publication typically lags filing by around 18 months, the most recent one or two years in any trend line will understate real filing activity; treat the tail of the chart as a floor, not a ceiling.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 1,001 records: how filing activity has moved year over year, and which IPC subclasses carry the claim density within that set.
A field past its filing peak
Filings peaked at 67 in 2017 and had fallen to a midpoint of 38 by 2022, with 2026 showing only 1 filing so far — consistent with the usual publication lag but also with a broader flattening trend across the period rather than sustained growth.
Nucleic-acid chemistry anchors the field
C07H (sugars and nucleic acids) appears on 88.3% of the 1,001 records, far ahead of C12N genetic-engineering art (22.3%) and C12Q enzyme/DNA measurement art (18.6%). Process-side classes — B01J catalysis (10.1%) and G01N analytical testing (9.0%) — are present but comparatively under-represented, which is one reason process and purification claims read thinner than composition-of-matter claims across this corpus.
Shares are the percentage of the 1,001 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Oligonucleotide Synthesis and Manufacturing with Eureka
This page is one run against one query. Ask Eureka your own question about oligonucleotide synthesis and manufacturing and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing and most-cited prior art
US6043353A — Reusable solid support for oligonucleotide synthesis, process for production thereof and process for use thereof
The patent discloses a solid support for oligonucleotide synthesis built from a defined chemical formula, with substituent groups drawn from specified alkyl, aryl and alkylaryl ranges and linking groups selected from oxygen, sulfur, sulfone and substituted nitrogen. It was filed under the PCT route and entered national phase via University Technologies International.Filed as PCT/CA96/00836, published WO97/23496 — an early example of solid-support reusability claims in this field.
View full filing| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5576427A | Acyclic nucleoside analogs and oligonucleotide sequences containing them | 2,192 |
| 2 | US6593081B1 | Production of anti-self antibodies from antibody segment repertoires and displayed on phage | 1,801 |
| 3 | US5451463A | Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides | 1,653 |
| 4 | US4973679A | Process for oligonucleotide synthesis using phosphoramidite intermediates | 1,428 |
| 5 | US6555313B1 | Production of anti-self antibodies from antibody segment repertoires and displayed on phage | 1,223 |
| 6 | US5428148A | N4- acylated cytidinyl compounds useful in oligonucleotide synthesis | 815 |
| 7 | US6521427B1 | Method for the complete chemical synthesis and assembly of genes and genomes | 733 |
| 8 | US6436675B1 | Use of codon-varied oligonucleotide synthesis for synthetic shuffling | 586 |
| 9 | US5141813A | Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis | 510 |
| 10 | US5889136A | Orthoester protecting groups in RNA synthesis | 490 |
Citation counts favour older filings simply because they have had more time to accumulate citations within the searched corpus — read them as a signal of influence on later filers, not as a measure of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data says about where this field stands
Four read-outs from the same 1,001-record set: concentration at the top, classification balance, jurisdictional spread and citation influence.
Leadership is real but not exclusive
The top five assignees account for 230 of the 1,001 records in scope, and the top ten hold 357 — over a third of the field. That leaves close to two-thirds of filings spread across a long tail of smaller entrants, including academic and university-linked assignees.
Composition claims outweigh process claims
C07H nucleic-acid chemistry touches the large majority of records, while process-oriented classes such as B01J (10.1%) and G01N (9.0%) appear far less often. That imbalance suggests scale-up and purification process claims are comparatively less crowded than composition-of-matter claims.
Activity has cooled from its peak
Filings peaked at 67 in 2017, fell to a midpoint of 38 by 2022, and the partial 2026 count of 1 reflects both the ongoing decline and the usual reporting lag. Read the recent years as a floor rather than a definitive drop-off.
US and Europe carry most of the filing weight
The United States leads with 308 records, ahead of the EPO at 201 and WIPO/PCT filings at 159. Australia, Canada and Austria each show smaller but non-trivial counts, indicating applicants are pursuing multi-jurisdiction protection rather than filing narrowly.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to oligonucleotide synthesis and manufacturing, with the prior art for and against each one.
Assignee landscape and where the openings sit
The ranked leaders sit atop a long tail of single- and few-filing entrants — a pattern typical of chemistry-heavy fields where the core composition art was staked out early and later entrants file narrower, process-specific claims.
A clear leader, not a monopoly
The leading assignee holds 72 records, more than double the fifth-place count of 33, but still well short of dominating the 1,001-record field. Momentum data shows even leading assignees posting flat or zero filings in the latest tracked year, consistent with the field's overall cooling trend.
Collaboration is limited and concentrated
Only 10 co-assignee pairs appear in this corpus, and the strongest pairs link a single pharmaceutical assignee with named individual inventors rather than broad corporate partnerships. This points to synthesis IP being built mostly in-house rather than through joint filings.
Recent-year activity has gone quiet across leaders
Several of the most active historical assignees show zero filings in the latest tracked year, and the one assignee with any recent activity recorded a year-on-year decline. That combination — a settled leaderboard with little fresh filing — is a signal the core chemistry claims may already be staked out.
| Assignee | Recent year | YoY |
|---|---|---|
| Wave Life Sciences Ltd | 1 | -50% |
| Ionis Pharmaceuticals Inc | 0 | — |
| Idera Pharmaceuticals Inc | 0 | — |
| University Technologies International Inc | 0 | — |
| Avecia Biotech | 0 | — |
| La Jolla Pharmaceutical Co | 0 | — |
| Agilent Technologies Inc | 0 | -100% |
| Alnylam Pharmaceuticals Inc | 0 | — |
Where to take this analysis
The landscape points to a field with settled composition-of-matter claims and thinner coverage on process and scale-up. The next step is testing a specific claim idea against this same corpus.
Pressure-test a solid-support or purification claim
Run a candidate claim on solvent reduction, continuous-flow coupling or solid-support regeneration against the C07H-heavy prior art in this set to see how much clearance actually exists.
Explore this in Eureka →Watch the leaders' recent filings, not just their totals
Several top assignees show zero or declining filings in the latest tracked year — worth monitoring whether that reflects a maturing core patent estate or a shift in filing strategy toward trade secret protection for scale-up know-how.
Track assignee activity in Eureka →Common questions about oligonucleotide synthesis patents
Within this 1,001-record dataset, one assignee leads with 72 records, well ahead of the fifth-ranked assignee at 33. The top five assignees combined hold 23.0% of all records, and the top ten hold 35.7%, so while there is a clear leader, well over half the field is spread across a long tail of smaller filers, including university and academic assignees. This pattern is typical of chemistry fields where foundational composition claims were filed early by a small group and later activity comes from narrower process or application-specific filings.
Filing activity has slowed from its peak. Annual filings hit 67 in 2017, had fallen to 38 by the 2022 midpoint, and show only 1 filing so far in the partial 2026 year. Because publication typically lags actual filing by around 18 months, the most recent one to two years will always look artificially low, but the multi-year trend from 2017 to 2022 is a genuine decline rather than a reporting artifact.
C07H, covering sugars and nucleic acids, appears on 88.3% of the 1,001 records and is by far the dominant classification. C12N genetic-engineering art (22.3%) and C12Q enzyme and DNA measurement art (18.6%) follow at a distance, while process-oriented classes like B01J catalysis (10.1%) and G01N analytical testing (9.0%) are comparatively thin. Because a single record can carry multiple IPC classes, these percentages sum to well over 100% of the record total and should not be read as mutually exclusive categories.
The classification data suggests process and analytical claims are less crowded than core chemistry claims: B01J (catalysis and adsorption processes) sits at only 10.1% of records and G01N (analytical testing) at 9.0%, versus 88.3% for C07H composition chemistry. Practically, that points toward openings in areas like continuous-flow coupling, solvent-reduction process claims, reusable solid-support regeneration, and in-line purification analytics — areas adjacent to the core chemistry but not saturated by it. Any specific claim idea should still be checked against the full corpus before filing, since class-level thinness does not guarantee an individual claim is clear.
It is moderately concentrated. The top five assignees account for 230 of the 1,001 records in scope (23.0%), and the top ten account for 357 (35.7%) — meaningful concentration, but not a lockout, since the ranked leaders are drawn from a pool of 100 tracked assignees and nearly two-thirds of records sit outside the top ten. Co-assignee collaboration is also limited, with only 10 identified co-filing pairs, suggesting most of the concentrated filing happens within single organizations rather than through joint ventures.
Research Oligonucleotide Synthesis and Manufacturing in depth with Eureka
Go past this page: query the whole oligonucleotide synthesis and manufacturing corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.